Short radiation plus chemotheapy and immunotherapy before surgery for junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with adenocarcinoma at the junction of the esophagus and stomach that has not spread beyond the local area.
- You cannot have received any prior cancer treatment for this condition.
- You must be in generally good health (able to do daily activities without help) and have adequate organ function (like liver, kidney, and blood counts).
- You must not have a genetic marker called MSI-H/dMMR in your tumor, active autoimmune disease, or a history of heavy bleeding or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.